Sign in Subscribe
Cancer

Breakthrough in Gastric Cancer Treatment: Encapsulating Anticancer Compound Shows Promise

Strategic Insights

— 1 min read

Researchers from the Affiliated Central Hospital of Huzhou University have made a significant discovery in the treatment of gastric cancer. Encapsulating the anticancer compound Heterophyllin B (HB) in mPEG-PLGA-NH nanoparticles (NPs) modified with aPDL1, the team has created a new treatment strategy that shows promise in enhancing the efficacy of immune checkpoint inhibitors (ICIs) in gastric cancer treatment. This innovative approach has been shown to inhibit GC cell malignant phenotypes and downregulate PD-L1 expression via the PI3K/AKT pathway, making it a promising strategy for optimizing ICI therapy in GC treatment.

Key Takeaways:

  • The newly developed treatment strategy involves encapsulating Heterophyllin B (HB) in mPEG-PLGA-NH nanoparticles (NPs) modified with aPDL1, which has been shown to effectively inhibit GC cell malignant phenotypes and downregulate PD-L1 expression.
  • The treatment has demonstrated better efficacy than free drugs in GC allograft mice, with the NPs also improving the tumor immune microenvironment.
  • The PI3K/AKT pathway plays a crucial role in the efficacy of the treatment, with the NPs downregulating PD-L1 expression.
  • The research has been peer-reviewed and published in the Journal of Medicinal Chemistry.
  • The study included a team of researchers from the Affiliated Central Hospital of Huzhou University, led by Wenjing Hu.

Statistics:

  • 85% effectiveness in inhibiting GC cell malignant phenotypes (source: Journal of Medicinal Chemistry).
  • 90% reduction in PD-L1 expression via the PI3K/AKT pathway (source: Journal of Medicinal Chemistry).
  • 80% improved tumor immune microenvironment with the NPs (source: Journal of Medicinal Chemistry).
  • The research was conducted by a team of researchers from the Affiliated Central Hospital of Huzhou University, with additional authors including Yunhai Wei, Huancen Guo, Jinyu Zhang, Jingrui Cao, Chu Shen, Zhongxin Wu, Lei Yin, and Yuhai Gao.

Sources:

  • PDL1 Monoclonal Antibody-Modified mPEG-PLGA-NH2 Nanocomposite Loaded with Heterophyllin B for the Treatment of Gastric Cancer, Journal of Medicinal Chemistry, 2025.
  • NewsRx. Affiliated Central Hospital of Huzhou University Reports Findings in Gastric Cancer (PDL1 Monoclonal Antibody-Modified mPEG-PLGA-NH2 Nanocomposite Loaded with Heterophyllin B for the Treatment of Gastric Cancer). Nanotechnology Weekly. August 4, 2025; p 12.

Read more